Dermata Therapeutics has reported positive topline data from the Phase Ib clinical trial where its product candidate, DMT310, was assessed…
19 Oct 2021
Entasis reports positive data from Phase III Acinetobacter drug trial
Entasis Therapeutics has reported positive topline data from the international Phase III ATTACK clinical trial of sulbactam-durlobactam (SUL-DUR) drug in people with Acinetobacter baumannii-caused infections. The gram-negative, opportunistic human pathogen…
19 Oct 2021
Valneva’s Covid-19 vaccine meets co-primary goals in Phase III trial
Valneva has reported that its inactivated, adjuvanted Covid-19 vaccine candidate, VLA2001, met the co-primary goals of the Phase III Cov-Compare clinical trial in adolescent and adult subjects. VLA2001 comprises inactivated…
18 Oct 2021
Innovent’s sintilimab meets primary goal of Phase III lung cancer trial
Innovent Biologics has reported that its sintilimab met the prespecified primary goal in the ORIENT-31 clinical trial in epidermal growth factor receptor (EGFR)-mutated nonsquamous non-small cell lung cancer (nsqNSCLC) patients.…
18 Oct 2021
Emergent commences Phase III trial of single-dose chikungunya vaccine
Emergent BioSolutions has dosed the first subject in the Phase III clinical trial of its single dose investigational chikungunya virus (CHIKV) vaccine candidate, CHIKV VLP. It is being developed for…
18 Oct 2021
Biogen’s tofersen fails to meet primary goal in Phase III ALS trial
Biogen has reported that its investigational antisense drug, tofersen (BIIB067), failed to meet the primary goal of the Phase III VALOR clinical trial in superoxide dismutase 1 (SOD1) amyotrophic lateral…
18 Oct 2021
AstraZeneca’s Imfinzi combo boosts survival in liver cancer trial
AstraZeneca has reported positive high-level results from the Phase III HIMALAYA clinical trial of Imfinzi (durvalumab) plus tremelimumab as a first-line therapy for unresectable hepatocellular carcinoma (HCC) patients. A human…
© Copyright Verdict Media Limited 2021
Powered by
